PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Akston Biosciences Corporation., 100 Cummings Center, Suite 454C, Beverly, MA 01915, United States.\', \'Biomere Biomedical Research Models, 57 Union St., Worcester, MA 01608, United States.\', \'Feigin ABSL-3 Facility, Baylor, College of Medicine, 1102 Bates Ave, 300.15, Houston, TX 77030, United States.\', \'BIOQUAL, Inc., 9600 Medical Center Drive, Suite 101, Rockville, MD 20850-3336, United States.\', \'Primate Assay Laboratory, CA National Primate Research Center, University of California, Davis, CA 95616, United States.\', \'Sinclair Research Center, 562 State Road DD, Auxvasse, MO 65231, United States.\', \'Pharmaceutical Research Associates Group B.V., Amerikaweg 18, 9407 TK Assen, Netherlands.\', \'Akston Biosciences Corporation., 100 Cummings Center, Suite 454C, Beverly, MA 01915, United States. Electronic address: todd.zion@akstonbio.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0264-410X(21)01294-910.1016/j.vaccine.2021.09.077
?:doi
?:hasPublicationType
?:journal
  • Vaccine
is ?:pmid of
?:pmid
?:pmid
  • 34642088
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.863
?:rankingScore_hIndex
  • 159
is ?:relation_isRelatedTo_publication of
?:title
  • Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34642088>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34642088>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all